新诊断多发性骨髓瘤患者中18F-FDG正电子发射断层扫描-计算机断层扫描的应用及预后价值
该研究回顾性分析了313例新诊断多发性骨髓瘤患者在治疗前60天内进行的PET-CT检查结果,发现存在至少3个局灶性病变和髓外病变均与较差的总生存期相关,而SUVmax无明确预测预后的截断值。
要点
- 75%(234/313)患者存在局灶性病变,12%(38/313)存在髓外病变。
- 至少3个局灶性病变患者中位OS为57.8个月,少于3个者为103.6个月(P=0.003)。
- 有髓外病变患者中位OS为45.5个月,无髓外病变者为71.8个月(P=0.004)。
核心结论
- PET-CT是评估疾病负担的有价值工具,可为接受新型药物治疗的新诊断骨髓瘤患者提供预后信息。
研究设计与样本
- 回顾性队列研究,纳入2005年4月至2017年6月期间在新诊断后60天内(治疗开始前)接受PET-CT检查的患者313例。
主要发现
- 234例(75%)患者存在局灶性病变,其中182例(58%)有至少3个局灶性病变,38例(12%)有髓外病变,204例(65%)有记录的骨髓瘤性溶骨性病变。
- 整个队列的中位最大标准化摄取值(SUVmax)为5.9(范围1.5-48.3)。
- 存在至少3个局灶性病变和髓外病变均预测较差的总生存期(OS);至少3个局灶性病变患者中位OS为57.8个月,少于3个者中位OS为103.6个月(P=0.003)。
- 有髓外病变患者中位OS为45.5个月,无髓外病变者中位OS为71.8个月(P=0.004)。
- 无明确的SUVmax截断值可预测无进展生存期或OS。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Positron emission tomography-computed tomography (PET-CT) can identify bony lesions, assess disease burden, and detect extramedullary disease (EMD) in patients with multiple myeloma. We retrospectively reviewed records of patients who underwent PET-CT within 60 days of a new diagnosis (before therapy commenced) to identify the nature and prognostic impact of PET-CT abnormalities. Patients (N = 313) were seen from April 2005 through June 2017. Of the 234 patients (75%) with focal lesions (FLs), 182 (58%) had at least 3 FLs, 38 (12%) had EMD, and 204 (65%) had documented myelomatous lytic lesions. The median maximum standardized uptake value (SUVmax ) for the entire cohort was 5.9 (range 1.5-48.3). Presence of at least 3 FLs and EMD predicted inferior overall survival (OS); median OS was 57.8 months for patients with 3 or more FLs and 103.6 months for patients with fewer than 3 FLs (P = .003). The median OS was 45.5 and 71.8 months for patients with and without EMD, respectively (P = .004). No clear SUVmax cutoff was predictive of progression-free survival or OS. PET-CT is a valuable tool for assessing disease burden and could provide prognostic information about a contemporary cohort of patients with newly diagnosed myeloma who received treatment with novel agents.
引用
- Aljama MA, Sidiqi MH, Buadi FK, et al. Utility and prognostic value of 18 F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. Am J Hematol. 2018. PMID: 30194770. doi:10.1002/ajh.25279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。